Bionic Technologies Transforming the Science of Healthcare Delivery

Clinical and Translational Science

Volumn 4, Issue 2, 2011, Pages 84-86

  Waldman, Scott A ^a   Terzic, Andre ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIONICS; BIOSENSOR; BIOTECHNOLOGY; HEALTH CARE DELIVERY; HEALTH SERVICE; NOTE; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

BIOMEDICAL TECHNOLOGY; BIONICS; BIOSENSING TECHNIQUES; DELIVERY OF HEALTH CARE; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 79953311867     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2011.00271.x     Document Type: Note

References (26)

1. Piquette-Miller M, Grant DM. The art and science of personalized medicine. Clin Pharmacol Ther. 2007; 81: 311-315.
2. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Clin Pharmacol Ther. 2007; 81: 164-169.
3. Waldman S, Terzic A. Targeted diagnostics and therapeutics for individualized patient management. Biomark Med. 2007; 1: 3-8.
4. Waldman SA, Kraft WK, Nelson TJ, Terzic A. Experimental therapeutics: a paradigm for personalized medicine. Clin Transl Sci. 2009; 2: 436-438.
5. Lesko LJ. Personalized medicine: elusive dream or imminent reality Clin Pharmacol Ther. 2007; 81: 807-816.
6. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther. 2007; 81: 104-107.
7. Waldman SA, Terzic A. Molecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy. Clin Transl Sci. 2009; 2: 6-8.
8. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science. 2004; 306: 640-643.
9. Hood L, Perlmutter RM. The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol. 2004; 22: 1215-1217.
10. Silver PA, Way JC. Molecular systems biology in drug development. Clin Pharmacol Ther. 2007; 82: 586-590.
11. Waldman SA, Terzic A. Clinical and translational science: from bench-bedside to global village. Clin Transl Sci. 2010; 3: 254-257.
12. Cortese DA. A vision of individualized medicine in the context of global health. Clin Pharmacol Ther. 2007; 82: 491-493.
13. Waldman SA, Terzic A. Individualized medicine and the imperative of global health. Clin Pharmacol Ther. 2007; 82: 479-483.
14. Waldman SA, Terzic A. Molecular therapy drives patient-centric health care paradigms. Clin Transl Sci. 2010; 3: 170-171.
15. Waldman SA, Terzic A. Molecular therapeutics from knowledge to delivery. Clin Pharmacol Ther. 2010; 87: 619-623.
16. Cardiovascular Disease Statistics. 2011. Available from: Cited January 29, 2011.
17. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685-1695.
18. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 24 January 2011; CIR.0b013e31820a55f5. [Epub ahead of print.
19. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008; 359: 938-949.
20. Nallamothu BK, Bradley EH, Krumholz HM. Time to treatment in primary percutaneous coronary intervention. N Engl J Med. 2007; 357: 1631-1638.
21. Myerburg RJ. Implantable cardiovertereter-defibrillators after myocardial infarction. N Engl J Med. 2008; 359: 2245-2253.
22. Keenan DB, Cartaya R, Mastrototaro JJ. The pathway to the closed-loop artificial pancreas: research and commercial perspectives. Pediatr Endocrinol Rev. 2010; 7(Suppl 3): 445-451.
23. Ramanujam N. Commercialization of implantable biosensor technology in healthcare. Philadelphia University of Pennsylvania; 2006.
24. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT. Clinically available pharmacogenomics tests. Clin Pharmacol Ther. 2009; 86: 109-113.
25. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007; 81: 328-345.
26. Wilson C, Schulz S, Waldman SA. Biomarker development, commercialization, and regulation: individualization of medicine lost in translation. Clin Pharmacol Ther. 2007; 81: 153-155.